J&J's Xarel­to, Amar­in's Vas­cepa are cost-ef­fec­tive, not bud­get friend­ly — ICER

ICER, an in­creas­ing­ly in­flu­en­tial cost-ef­fec­tive­ness watch­dog in the Unit­ed States, has con­clud­ed in its re­view of treat­ments for car­dio­vas­cu­lar dis­ease that while the cost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER